Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study

Abstract In the United States, 100,000–300,000 patients die from venous thromboembolism (VTE) each year, with more than 500,000 people related hospitalizations. While in Europe, 500,000 people die from VTE each year. Patients with rheumatoid arthritis are at increased risk of VTE. The use of biologi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chao-Ping Chen, Pei-Tseng Kung, Wen-Yu Chou, Wen-Chen Tsai
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b2ae2c13e19b4187aadd387eb9e1870a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b2ae2c13e19b4187aadd387eb9e1870a
record_format	dspace
spelling	oai:doaj.org-article:b2ae2c13e19b4187aadd387eb9e1870a2021-12-02T18:53:14ZEffect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study10.1038/s41598-021-96508-z2045-2322https://doaj.org/article/b2ae2c13e19b4187aadd387eb9e1870a2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96508-zhttps://doaj.org/toc/2045-2322Abstract In the United States, 100,000–300,000 patients die from venous thromboembolism (VTE) each year, with more than 500,000 people related hospitalizations. While in Europe, 500,000 people die from VTE each year. Patients with rheumatoid arthritis are at increased risk of VTE. The use of biologics in patients with rheumatoid arthritis may be associated with an increased risk of VTE. We identified all patients who had been newly approved for Catastrophic Illness Card of rheumatoid arthritis extracted the claims data from the National Health Insurance research database and Registry for Catastrophic Illness Patient Database from 2003 to 2016. VTE was defined as the presence of inpatient VTE diagnostic codes (including DVT or PE) according to the discharge diagnosis protocol. An analysis of VTE variables indicated that the incidence of VTE in the biologic group (14.33/10,000 person-years) was higher than that in the conventional drug group (12.61/10,000 person-years). As assessed by the Cox proportional hazards model, the relative HR for VTE in the biologic group (HR: 1.11; 95% CI 0.79–1.55) versus that in the conventional drug group did not reach a significant difference. In conclusion, this study found no significant differences in risk were observed between the use of conventional DMARDs and biologics.Chao-Ping ChenPei-Tseng KungWen-Yu ChouWen-Chen TsaiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chao-Ping Chen Pei-Tseng Kung Wen-Yu Chou Wen-Chen Tsai Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study
description	Abstract In the United States, 100,000–300,000 patients die from venous thromboembolism (VTE) each year, with more than 500,000 people related hospitalizations. While in Europe, 500,000 people die from VTE each year. Patients with rheumatoid arthritis are at increased risk of VTE. The use of biologics in patients with rheumatoid arthritis may be associated with an increased risk of VTE. We identified all patients who had been newly approved for Catastrophic Illness Card of rheumatoid arthritis extracted the claims data from the National Health Insurance research database and Registry for Catastrophic Illness Patient Database from 2003 to 2016. VTE was defined as the presence of inpatient VTE diagnostic codes (including DVT or PE) according to the discharge diagnosis protocol. An analysis of VTE variables indicated that the incidence of VTE in the biologic group (14.33/10,000 person-years) was higher than that in the conventional drug group (12.61/10,000 person-years). As assessed by the Cox proportional hazards model, the relative HR for VTE in the biologic group (HR: 1.11; 95% CI 0.79–1.55) versus that in the conventional drug group did not reach a significant difference. In conclusion, this study found no significant differences in risk were observed between the use of conventional DMARDs and biologics.
format	article
author	Chao-Ping Chen Pei-Tseng Kung Wen-Yu Chou Wen-Chen Tsai
author_facet	Chao-Ping Chen Pei-Tseng Kung Wen-Yu Chou Wen-Chen Tsai
author_sort	Chao-Ping Chen
title	Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study
title_short	Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study
title_full	Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study
title_fullStr	Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study
title_full_unstemmed	Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study
title_sort	effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b2ae2c13e19b4187aadd387eb9e1870a
work_keys_str_mv	AT chaopingchen effectofintroducingbiologicstopatientswithrheumatoidarthritisontheriskofvenousthromboembolismanationwidecohortstudy AT peitsengkung effectofintroducingbiologicstopatientswithrheumatoidarthritisontheriskofvenousthromboembolismanationwidecohortstudy AT wenyuchou effectofintroducingbiologicstopatientswithrheumatoidarthritisontheriskofvenousthromboembolismanationwidecohortstudy AT wenchentsai effectofintroducingbiologicstopatientswithrheumatoidarthritisontheriskofvenousthromboembolismanationwidecohortstudy
_version_	1718377347733782528

Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study

Ejemplares similares